Drugs / OHR/AVR118
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01206335 | Sep 2010 → Dec 2012 | eating disorder | Ohr Pharmaceutical Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OHR/AVR118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01206335 ↗ |
| Route | Subcutaneous | “OHR/AVR118 given subcutaneously at 4mL per day” NCT01206335 ↗ |